Rabbit Recombinant Monoclonal CD99 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Involved in T-cell adhesion processes and in spontaneous rosette formation with erythrocytes. Plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1. Involved in T-cell adhesion processes (By similarity).
MIC2, MIC2X, MIC2Y, MIC2, CD99, MIC2X, MIC2Y, CD99 antigen, 12E7, E2 antigen, Protein MIC2, T-cell surface glycoprotein E2
Rabbit Recombinant Monoclonal CD99 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR3097Y
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
CD99 also known as MIC2 or HO36 is a transmembrane protein of approximately 32-35 kDa. Expressed mainly on the surface of human cells CD99 plays a role in several physiological processes. It is prominently found on T cells B cells granulocytes and some capillary endothelial cells. The protein interacts with homophilic binding partners and influences various cellular functions depending on its location and cellular context. Immunohistochemistry for CD99 (CD99 IHC) is commonly used in research and diagnostic settings to study its involvement and presence in tissues.
CD99 functions as a modulator in cell adhesion and migration. It facilitates the separation of leukocytes from the endothelium during transendothelial migration impacting the immune response and inflammation. CD99 is not part of a complex itself but interacts with extracellular matrix (ECM) components to perform its role. It contributes to the regulation of cell death pathways showcasing its versatility in maintaining cellular homeostasis.
CD99 primarily participates in the regulation of T-cell adhesion and transmigration pathways. It supports the E-selectin and integrins pathway which is important for T-cell migration to sites of inflammation. CD99 works in conjunction with proteins like ICAM-1 and VCAM-1 assisting these proteins in facilitating immune cell movement and interactions. Its involvement in these pathways highlights its significance in immune surveillance and response modulation.
CD99 shows a notable connection with Ewing sarcoma and T-cell acute lymphoblastic leukemia (T-ALL). It is highly expressed in Ewing sarcoma a malignant bone tumor and can aid in diagnostic identification alongside other markers such as HOXA9. Furthermore its expression profiles in T-ALL patients suggest a potential role in the progression or maintenance of the disease. CD99's interactions with these malignancies make it a potential target in therapeutic research exploring pathways and molecules that might modulate its expression or function.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com